ASCO 2026: AI Challenges a Breast Cancer Standard

1

The Artera breast model is an FDA-cleared AI tool that integrates digital pathology and clinical variables for breast cancer risk stratification.
2

In a study of over 300 early-stage breast cancer patients, the Artera AI tool outperformed the 21-gene recurrence score in prognostic value.
3

Patients with concordantly low scores from both Artera and Oncotype had no distant recurrences at 10 years, indicating strong prognostic accuracy.
4

Discordant scores showed a significant difference in 10-year distant metastasis rates, with 20% recurrence in patients with Oncotype low and Artera high.
5

The study suggests that the Artera AI tool provides additional prognostic information beyond traditional recurrence score categories.

1